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as (APO-1/CD95) is the prototypic death receptor, and
the molecular mechanisms of Fas-induced apoptosis
are comparably well understood. Here, we show that
Fas activates NF
 
 
 
B via a pathway involving RIP, FADD, and
caspase-8. Remarkably, the enzymatic activity of the latter
was dispensable for Fas-induced NF
 
 
 
B signaling pointing
to a scaffolding-related function of caspase-8 in nonapop-
totic Fas signaling. NF
 
 
 
B was activated by overexpressed
FLIP
 
L
 
 and FLIP
 
S
 
 in a cell type–speciﬁc manner. However, in
the context of Fas signaling both isoforms blocked FasL-
F
 
induced NF
 
 
 
B activation. Moreover, down-regulation of
both endogenous FLIP isoforms or of endogenous FLIP
 
L
 
alone was sufﬁcient to enhance FasL-induced expression of
the NF
 
 
 
B target gene IL8. As NF
 
 
 
B signaling is inhibited
during apoptosis, FasL-induced NF
 
 
 
B activation was most
prominent in cells that were protected by Bcl2 expression
or caspase inhibitors and expressed no or minute amounts
of FLIP. Thus, protection against Fas-induced apoptosis in a
FLIP-independent manner converted a proapoptotic Fas
signal into an inﬂammatory NF
 
 
 
B-related response.
 
Introduction
 
In susceptible cells, membrane FasL, agonistic Fas-specific
antibodies, and secondarily aggregated soluble FasL induce
reorganization of inactive, preassembled Fas complexes to
supramolecular Fas clusters having the capacity to signal
apoptosis. Upon formation of apoptosis-competent signal-
ing clusters, Fas is able to recruit the cytoplasmic death
domain–containing adaptor protein FADD (Fas-associated
death domain protein), which in turn recruits procaspase-8.
In context of this death-inducing signaling complex (DISC),
procaspase-8 is activated by dimerization (Boatright et al.,
2003; Donepudi et al., 2003), resulting in autoproteolytic
processing and release of the mature and active heterotet-
rameric form of the enzyme. In so called type I cells, Fas-
activated caspase-8 is sufficient to trigger efficient activation
of effector caspases, especially caspase-3, resulting in execution
of the final steps of apoptosis (Barnhart et al., 2003). In con-
trast, in type II cells, caspase-8 activation is less prominent
and/or caspase-3 activation is counteracted by members of
the inhibitor of apoptosis (IAP) protein family (Barnhart et
al., 2003). In these cells, robust induction of apoptosis is
therefore dependent on mitochondrial amplification mecha-
nisms that can be triggered by caspase-8–mediated cleavage
of Bid, a BH3-only protein. The resulting truncated Bid
fragment induces Bax/Bak-dependent release of apoptogenic
proteins from mitochondria including Smac/Diablo (the
second mitochondria-derived activator of caspase/direct IAP
binding protein with low PI), HtrA2/Omi, and cytochrome
 
c
 
 (Barnhart et al., 2003). Although cytosolic cytochrome 
 
c
 
assembles with ATP and the scaffold protein Apaf-1 (apop-
tosis promoting factor-1) to the apoptosome (Shi, 2002),
which activates caspase-9, Smac/Diablo and HtrA2/Omi
block caspase inhibition by members of the IAP protein
family (Verhagen and Vaux, 2002). Both mechanisms en-
hance the effect of initially DISC-activated caspase-8. Due
to cell type–specific relative contributions of these proapop-
totic mitochondrial events to Fas-induced apoptosis, type I
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and type II cells have been experimentally defined in vitro by
overexpression of Bcl2 or other proteins interfering with the
Bax/Bak-mediated release of apoptogenic factors. In type I
cells, death receptor–induced apoptosis was not affected by
Bcl2 expression, whereas in type II cells Bcl2 expression in-
hibited or attenuated Fas-induced apoptosis. If and to which
extent the release of mitochondrial proteins can contribute
to the apoptotic effects of Fas in vivo is a matter of debate.
Although some reports found a protective effect in hepato-
cytes of Bcl2 transgenic mice against Fas-mediated apoptosis
induced by agonistic antibodies (Lacronique et al., 1996;
Rodriguez et al., 1996), others found no protective effect by
Bcl2 when Fas was challenged with aggregated soluble FasL
(Huang et al., 1999). The latter study has shown in vitro
that agonistic Fas-specific antibodies, but not cross-linked
FasL, are much more active on type I cells than on type II
cells. Therefore, these apparent discrepancies in various
studies might be caused by analyzing Fas signals of different
strengths. Embryonal fibroblasts of Apaf1-deficient mice
(Cecconi et al., 1998) displayed somewhat lower Fas sensi-
tivity, and Fas-mediated liver toxicity is also reduced in mice
deficient for Bid (Yin et al., 1999) or Bak and Bax (Wei et
al., 2001). In contrast, thymocytes of Bcl2 transgenic mice
(Strasser et al., 1995; Huang et al., 1999), of caspase-9–defi-
cient mice (Hakem et al., 1998), and of Bak/Bax double-
deficient mice (Lindsten et al., 2000) as well as Bcl2-express-
ing granulocytes (Villunger et al., 2000) showed no significant
decrease in Fas sensitivity, suggesting a cell type–specific
nonessential contribution of the intrinsic mitochondrial ap-
optotic pathway to Fas-induced apoptosis.
Fas-induced apoptosis is inhibited by the long and short
isoform of the cellular FLICE-inhibitory protein cFLIP. Simi-
lar to caspase-8, FLIP
 
L
 
 (FLIP-long) consists of two amino-ter-
minal death effector domains followed by an unfunctional
caspase homology domain (Krueger et al., 2001; Thome and
Tschopp, 2001). FLIP
 
S
 
 (FLIP-short) has no caspase homol-
ogy domain and mainly consists of the two death effector
domains of the long isoform. Although FLIP
 
S
 
 blocks auto-
proteolytical maturation of Fas-FADD–bound caspase-8
completely, FLIP
 
L
 
 arrests this process at an intermediate state
(Krueger et al., 2001; Thome and Tschopp, 2001).
Although Fas has been predominantly recognized as an
apoptosis inducer, there is increasing evidence for additional
apoptosis-independent functions of Fas, including induction
of proliferation in T cells and fibroblasts, hepatocyte regen-
eration, chemokine production, DC regulation, and neurite
outgrowth (for review see Desbarats et al., 2003; Wajant et
al., 2003). However, the molecular mechanisms of Fas sig-
naling in most of these processes are poorly understood. In
this study, we identified FADD, caspase-8, and RIP as es-
sential components of Fas-induced NF
 
 
 
B signaling. More-
over, we showed that FLIP
 
S
 
 and especially FLIP
 
L
 
 have an in-
hibitory role in Fas-induced NF
 
 
 
B activation.
 
Results
 
Bcl2 expression in HT1080 and KB cells confers 
resistance against Fas-induced apoptosis
 
Active caspases cleave components of the NF
 
 
 
B signaling
cascade and efficiently inhibit activation of this pathway
during apoptosis (for review see Wajant et al., 2003). There-
fore, we decided to analyze FasL-induced NF
 
 
 
B signaling
and gene induction in cells protected from the apoptotic ac-
tion of FasL. This can be achieved in type I and type II cells
by inhibition of caspases; e.g., by pharmacological inhibitors
or by expression of FLIP and in vitro in type II cells, which
show a strong contribution of the intrinsic apoptotic path-
way to Fas-induced apoptosis, in addition by Bcl2 overex-
pression. We choose the latter possibility, in contrast to
pharmacological caspase-8 inhibitors and FLIP, as Bcl2 does
not target the Fas signaling complex and should therefore
have no influence on receptor proximal events in Fas signal-
ing. We used KB and HT1080 cells as well as transfectants
derived thereof that have been stably transfected with a GFP
fusion protein of Bcl2 (Fig. 1 A). FasL-induced apoptosis in
parental KB cells required sensitization by cycloheximide
(CHX), an inhibitor of protein synthesis. Parental HT1080
cells already underwent significant Fas-induced apoptosis in
the absence of CHX, but nevertheless responded more
strongly in the presence of CHX (unpublished data). Note-
worthily, the CHX concentrations used (2.5 
 
 
 
g/ml or less)
only reduced overall protein synthesis for 10 to 30% and re-
sulted only in marginal cell death even after extended incu-
bation times (unpublished data). Thus, in the time scale of
our analysis, CHX treatment predominantly affected expres-
sion levels of short-lived proteins including antiapoptotic
factors (e.g., FLIP). Parental KB and HT1080 cells both
have an ED50 value for FasL-induced apoptosis of around
0.3–2 ng/ml. The KB-GFP-Bcl2 transfectants have an
ED50 value of 
 
 
 
1 
 
 
 
g/ml and HT1080-GFP-Bcl2 cells
showed only marginal apoptosis (
 
 
 
10%) at FasL concentra-
tions 
 
 
 
1,000-fold higher than those necessary to kill the pa-
rental cells (Fig. 1 B). Next, we checked if KB and HT1080-
GFP-Bcl2 cells are protected against apoptosis induction by
cells expressing membrane FasL. For this purpose, we as-
sayed cocultures of the various cells with Rapo cells and
Rapo transfectants expressing membrane FasL (Fig. 1 C).
Rapo cells are a Jurkat clone devoid of Fas expression, and
these cells are therefore resistant against Fas-induced apopto-
sis. Rapo-FasL cells induced complete killing of KB and
HT1080 cells in coculture assays, whereas the parental Rapo
clone showed no effect. In contrast, KB-GFP-Bcl2 and
HT1080-GFP-Bcl2 cells were completely (KB) or largely
(HT1080) protected against the membrane FasL-expressing
Rapo cells. Apoptosis induction by Rapo-FasL was blocked
by the caspase inhibitor z-IETD-fmk and Fas-Comp, a pen-
tameric fusion protein containing the extracellular domain
of Fas (Fig. 1, D and E). Thus, in KB and HT1080 cells the
intrinsic apoptotic pathway makes a significant contribution
to Fas-induced apoptosis, even when Fas is stimulated with
membrane FasL and allows analysis of nonapoptotic Fas
signaling.
 
Fas-mediated NF
 
 
 
B activation and gene induction 
in Bcl2-protected cells
 
Next, we analyzed FasL-induced IL8 production, as this che-
mokine is a well established target gene of nonapoptotic Fas
signaling and of pivotal importance for FasL-induced tumor
cell rejection (for review see Wajant et al., 2003). Although in
KB cells there was only a minor increase in IL8 production 
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upon Fas stimulation, significant amounts of IL8 were
induced in HT1080 cells (Fig. 2 A). Remarkably, in the
presence of the caspase inhibitor z-VAD-fmk, which blocks
apoptosis and the NF
 
 
 
B inhibitory effects of caspases, FasL-
induced IL8 production in HT1080 cells was three to five
times higher. Similarly, the low induction of IL8 in KB cells
was also enhanced in the presence of z-VAD-fmk. In the pres-
ence of low doses of CHX (2.5 
 
 
 
g/ml), thus under circum-
stances where Fas induces activation of caspases and apoptosis,
FasL-induced IL8 production was almost completely blocked
in both cell lines. In the case of KB cells, there was a higher
basal IL8 production in the presence of CHX (Fig. 2 A).
However, when apoptosis induction was blocked by z-VAD-
fmk, FasL-induced IL8 production was restored and even sig-
nificantly higher than in the absence of CHX. These data not
only illustrate that the low concentrations of CHX used had
indeed no major effect on overall protein synthesis but also
suggest that CHX facilitates Fas-induced IL8 production by
bringing a short-lived inhibitory protein under a critical
threshold. Bcl2 expression was sufficient to substitute z-VAD-
fmk to allow enhanced FasL-mediated induction of IL8.
Thus, in HT1080-GFP-Bcl2 cells, FasL-induced IL8 produc-
tion reached comparable levels as in z-VAD-fmk–protected
parental HT1080 cells (Fig. 2 A). Treatment of HT1080-
GFP-Bcl2 cells with z-VAD-fmk did not lead to a further en-
hancement of IL8 production. In contrast to the parental cell
lines, CHX treatment did not interfere or even sensitize the
GFP-Bcl2 transfectants for FasL-induced IL8 production. In
the presence of CHX and the absence of apoptosis (z-VAD-
fmk and GFP-Bcl2 expression), FasL-induced IL8 levels al-
most reached values induced by TNF, which is a very potent
inducer of IL8 production (unpublished data). IL8 produc-
tion was similarly induced when membrane FasL-expressing
cells were used instead of cross-linked soluble FasL (Fig. 2 B).
Together, these data suggest that a CHX-sensitive, and there-
fore short-lived, protein exists that blocks both apoptosis and
gene induction by FasL upstream of Bcl2. In accordance with
the central role of NF
 
 
 
B in regulation of the IL8 gene (Hoff-
mann et al., 2002), FasL activated the NF
 
 
 
B pathway in
z-VAD-fmk– and Bcl2-protected cells (Fig. 3, A and B).
I
 
 
 
B
 
 
 
 degradation was transient and rapid upon TNF stimu-
lation (Fig. 3 B). In contrast, a delayed and sustained loss of
Figure 1. Bcl2 expression protects HT1080 and KB 
cells from Fas-mediated apoptosis. (A) FACS
® analysis 
of pools of HT1080 and KB cells stably transfected 
with GFP-Bcl2. (B) Indicated cells were seeded in 96-
well plates (20   10
3 per well) and challenged the 
next day with the indicated concentrations of soluble 
Flag-tagged FasL complexed with 0.5  g/ml of the 
Flag-specific mAb M2 in the presence of 2.5  g/ml 
CHX. After an additional 18 h, cell viability was deter-
mined by crystal violet staining. (C) Cells were seeded 
in 96-well plates overnight, and the next day the indi-
cated number of membrane FasL-expressing Rapo 
cells or parental Rapo cells were added to each well 
in the presence of 2.5  g/ml CHX. After 18 h, Rapo, 
Rapo-FasL, and dead cells were removed by two 
washes with PBS, and finally, the remaining viable 
cells were quantified by crystal violet staining. HT1080 
(D) and KB (E) cells were challenged with Rapo-FasL 
cells as described in C. However, this time either the 
HT1080 and KB cells were pretreated with 50  M of 
the caspase-8 inhibitor z-IETD-fmk or the Rapo-FasL 
cells with 4  g/ml of Fas-Comp. Viability data shown 
are averages and SDs of triplicates. 
372 The Journal of Cell Biology 
 
|
 
 
 
Volume 166, Number 3, 2004
 
I
 
 
 
B
 
 
 
 protein was observed after FasL treatment in KB and
HT1080 cells and in the corresponding Bcl2-transfectants in
the presence of 2.5 
 
 
 
g/ml CHX (Fig. 3 B). To analyze the
genes induced by FasL more comprehensively and, at the
same time, compare them to TNF, we determined the expres-
sion of 110 genes relevant to inflammation using a custom-
ized DNA oligonucleotide microarray developed in our labo-
ratory (Holzberg et al., 2003). In HT1080-GFP-Bcl2 cells, 40
genes were significantly expressed, 16 of which were induced
by FasL by at least 1.5-fold on average and 27 by TNF (Table
I). Inspection of the more strongly regulated genes revealed
that FasL and TNF, despite their different kinetics of NF
 
 
 
B
activation, induced an almost identical pattern of genes.
Moreover, many of the induced genes are established targets
Figure 2. FasL induces IL8 in Bcl2-protected HT1080 and KB cells. 
(A) Indicated cells were seeded in 96-well plates (20   10
3 per 
well). The next day, the medium was changed and cells were stimu-
lated with 200 ng/ml of soluble Flag-tagged FasL complexed with 
0.5  g/ml of the Flag-specific mAb M2 or 20 ng/ml TNF in the pres-
ence of the indicated reagents (20  M z-VAD-fmk; 2.5  g/ml CHX). 
After 6 h, supernatants were removed, cleared, and analyzed for 
their IL8 content using an IL8-specific ELISA. (B) Cells were seeded 
in 96-well plates (20   10
3 per well). The next day, the medium 
was changed and Rapo or Rapo-FasL cells (40   10
3 per well) were 
added for 6 h in the presence or absence of 20  M z-VAD-fmk and 
finally IL8 production was determined as in A. Data shown are aver-
ages and SDs of triplicates.
 
Table I.
 
Comparison of the effects of FasL and TNF on inducible 
inflammatory gene expression of HT1080-Bcl2 cells
 
Relative induction
FasL TNF
Accession number Gene Exp. 1 Exp. 2 Exp. 1 Exp. 2
 
Signalling molecules
NM_001165 hlAP-1
 
11.0 4.0 28.1 5.1
 
NM_020529 I
 
 
 
B-
 
 
 
7.5 7.4 9.3 9.1
 
NM_001561 ILA
 
2.7 0.9 7.4 1.9
 
NM_002229 JunB
 
4.1 2.0 3.0 2.7
 
NM_001166 hlAP-2 0.9 1.6 1.8 1.6
NM_031419 MAIL 1.8 1.2 1.6 1.8
NM_002228 c-Jun 1.3 1.4 0.9 0.8
Metabolic enzymes, miscellaneous
NM_002852 PTX3
 
6.0 5.1 15.3 9.8
 
NM_000636 MnSOD
 
2.8 1.5 6.5 5.1
 
NM_002575 PAI-2
 
3.2 1.4 5.0 3.2
 
NM_000161 GTP cyclohydrolase I 1.4 0.8 1.8 1.8
NM_001993 Tissue factor 1.5 1.0 1.1 0.9
NM_004385 Versican 1.3 0.5 1.0 1.1
NM_002032 Ferritin heavy chain 1.2 0.8 1.0 1.0
NM_000602 PAI-1 0.9 1.2 0.9 0.9
Proteases
NM_002428 MMP15
 
5.1 2.0 8.8 4.1
 
NM_004994 MMP9
 
2.1 1.4 5.9 5.4
 
NM_002427 MMP13 1.3 0.9 1.3 3.2
NM_002422 MMP3 1.0 0.8 1.4 1.2
Cytokines–cytokine receptors
NM_000575 IL-1 
 
 
 
4.9 2.3 9.1 3.9
 
NM_000758 GM-CSF
 
4.0 1.4 8.1 3.5
 
NM_000576 IL-1 
 
 
 
3.1 2.2 7.6 6.2
 
NM_001066 TNFR II 1.7 0.6 3.0 1.4
NM_000882 IL-12A (p35) 1.4 1.1 1.7 1.9
NM_002341 Lymphotoxin 
 
 
 
1.3 0.9 1.6 1.5
NM_002006 bFGF 1.1 0.7 1.4 1.1
NM_005228 EGFR 0.9 0.9 1.1 0.9
NM_003266 TLR 4 1.1 0.8 1.0 1.3
NM_000594 TNF 
 
 
 
1.4 1.9 0.9 1.6
NM_004513 IL-16 0.9 0.5 0.8 1.1
NM_001901 CTGF 1.7 0.9 0.7 0.5
Chemokines–chemokine receptors
NM_002982 CCL2
 
6.6 2.5 40.7 14.6
 
NM_000584 CXCL8
 
14.8 8.1 38.4 13.5
 
NM_002985 CCL5
 
1.2 0.9 2.3 1.5
 
NM_002986 CCL11
 
1.2 0.7 1.8 1.6
 
NM_001295 CCR1
 
1.6 0.8 1.5 2.1
 
NM_000648 CCR2b 1.1 0.8 0.9 1.1
Adhesion molecules
NM_000201 ICAM1
 
2.2 1.8 4.1 4.3
 
Acute phase genes
NM_000331 SAA 1
 
2.2 1.4 3.4 3.5
 
NM_001639 SAP 0.8 0.8 1.7 1.9
HT1080-Bcl2 cells were treated with 200 ng/ml FasL for 6 h or left untreated.
Parallel cells were treated with 20 ng/ml TNF for 6 h. Thereafter, total RNA was
isolated from all samples and used to prepare double-stranded cDNA followed
by cRNA synthesis. cRNA was labeled with Cy3 and hybridized independently
to DNA microarrays containing amino-modified oligonucleotide probes,
representing 110 genes relevant to inflammation as well as several housekeeping
genes. Fluorescence intensities of bound cRNAs were recorded, normalized,
and used to identify 40 inflammatory genes that were significantly expressed.
Alterations imposed by the FasL or TNF on the inducible or basal expression of
these genes were determined as a ratio of relative gene expression compared
with unstimulated cells. The results from two independent experiments are
shown (Exp. 1 and 2). Genes are arranged into functional groups and are ordered
according to their relative induction by TNF in Exp. 1. GenBank accession
numbers and gene names, respectively, are provided for identification. Genes
induced for more than twofold by TNF or FasL are in bold. 
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of the NF
 
 
 
B pathway; e.g., such as ICAM-1, CCL2, IL8,
JunB, or I
 
 
 
B
 
 
 
. Together, these studies demonstrated that at
least in vitro Bcl2 expression can convert a proapoptotic Fas
signal into an inflammatory NF
 
 
 
B-related response.
 
Fas-induced up-regulation of I
 
 
 
B
 
 
 
 occurs via FADD, 
caspase-8, and RIP
 
Next, we investigated Jurkat cells because for this cell type a
variety of clones are available with defects in the expression
of proteins related to NF
 
 
 
B and/or Fas signaling. In Jurkat
cells, FasL did not induce IL8. We analyzed instead I B ,
which is a bona fide NF B target gene (Karin and Ben-
Neriah, 2000). Jurkat cells are highly sensitive toward FasL-
induced apoptosis in the absence of CHX. To ensure analy-
sis of nonapoptotic Fas signaling, we blocked caspase activity
and apoptosis by adding z-VAD-fmk. Under these condi-
tions, all parental Jurkat strains responded to FasL treatment
with I B  induction (Fig. 4, A and B, left). First, we ana-
lyzed a Jurkat clone deficient in expression of NEMO/
IKK , a crucial component of the IKK complex (Karin and
Ben-Neriah 2000), which therefore fails to activate the
NF B signaling pathway in response to a variety of inducers
(Harhaj et al., 2000). In agreement with the idea that FasL-
induced up-regulation of I B  is due to the activation of
NF B, this effect was completely abolished in the NEMO/
IKK -deficient Jurkat clone (Fig. 4 A, middle). FasL-induced
up-regulation of I B  also occurred in the presence of high
concentrations of CHX (25–50  g/ml), which fully block
protein synthesis, indicating that I B  induction is a direct
consequence of Fas signaling (unpublished data). We also
analyzed Jurkat cells deficient in the expression of the serine/
threonine kinase RIP, which was originally identified as a
Figure 3. FasL induces NF B activation in Bcl2-
protected HT1080 and KB cells. (A) HT1080 
and HT1080-GFP-Bcl2 cells were stimulated 
with M2–cross-linked Flag-FasL (200 ng/ml) or 
TNF (20 ng/ml), and in the case of the parental 
cells, the presence of 20  M z-VAD-fmk. After 
3 h, cells were analyzed for NF B activation by 
electrophoretic mobility shift assay. (B) Indi-
cated cells were stimulated for varying times 
with cross-linked Flag-FasL or TNF, and I B  
degradation was determined by Western blot 
analysis of cytosolic extracts with an I B -spe-
cific antibody. To control protein loads, filters 
were reprobed with antitubulin antibodies. 
Where indicated, 20  M z-VAD-fmk and 2.5 
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death domain–containing Fas-interacting protein (Stanger
et al., 1995) and which plays an essential role in NF B acti-
vation by the death receptors TNF-R1 and TRAIL-R1 (Ting
et al., 1996; Kelliher et al., 1998; Lin et al., 2000). FasL-
induced up-regulation of I B  was completely blocked in
RIP-deficient Jurkat cells (Fig. 4 A, right), indicating that
this kinase is also critically involved in Fas-induced NF B
activation. Remarkably, induction of cJun, which is regu-
lated by AP1 and the JNK pathway, was only marginally af-
fected (Fig. 4 A).
FADD and caspase-8 are essential components of the
DISC of Fas (Barnhart et al., 2003) and are also indispens-
able for FasL-induced up-regulation of cFos, which occurs
in Jurkat cells under nonapoptotic circumstances (Siegmund
et al., 2001). Analysis of FADD and caspase-8–deficient Jur-
kat clones (Juo et al., 1998, 1999) revealed that both pro-
teins are also necessary for FasL-induced up-regulation of
I B  (Fig. 4 B). Fas signaling occurred in the presence of
z-VAD-fmk, when caspase-8 activity was completely blocked.
Thus, caspase-8 acts in FasL-induced NF B signaling in-
dependent from its enzymatic activity. Moreover, FasL-
induced cJun up-regulation was also completely blocked in
FADD and caspase-8–deficient clones (Fig. 4 B). Together
these data suggest that FADD and caspase-8 form a core sig-
naling complex with Fas, whose structural integrity is neces-
sary to allow activation of a diverse set of otherwise indepen-
dent signaling pathways.
FLIP inhibits Fas-mediated up-regulation 
of NF B target genes
Apoptosis induction and NF B activation by Fas bifurcate at
the level of FADD and caspase-8. Therefore, the potential
short-lived inhibitor, which concomitantly blocks apoptotic
and nonapoptotic Fas signaling, should target the Fas signal-
ing complex. As discussed in an earlier work (Wajant et al.,
2000), good candidates for such short-lived protein(s) are the
FLIP isoforms as they (a) act on the Fas DISC and (b) exert
the required high turnover (Fig. 5 A; Fulda et al., 2000; Le-
verkus et al., 2000a; Wajant et al., 2000; Kreuz et al., 2001).
In further agreement with a negative-regulatory role of FLIP
proteins in FasL-induced NF B signaling, we found that
FasL-induced up-regulation of I B  is completely absent in a
Jurkat clone stably transfected with FLIPL (Fig. 5 B). Notably,
the expression level of FLIPL in this clone does not exceed en-
dogenous FLIPL expression levels observed in other cell lines
or mature dendritic cells (Fig. 5, A and C; Kreuz et al., 2001).
A Jurkat clone transfected with FLIPS showed normal FasL-
induced up-regulation of I B  (unpublished data), but it
cannot be ruled out that this was due to limited expression of
FLIPS. Further, we observed that the FasL-induced response
pattern in primary cells also supports an NF B inhibitory role
of FLIP. In mature dendritic cells having high endogenous
levels of FLIP (Fig. 5 C; Leverkus et al., 2000b; Rescigno et
al., 2000; Willems et al., 2000), FasL showed no effect on
I B  expression (Fig. 5 D, middle), whereas in primary T
cells having barely detectable FLIP expression (Fig. 5 C; Irm-
ler et al., 1997), I B  mRNA was readily induced (Fig. 5 D,
left and right). In the latter case, addition of z-VAD-fmk was
required, as otherwise apoptosis interferes with the NF B re-
sponse. To analyze the role of FLIPL and FLIPS in Fas-medi-
ated gene induction in KB and HT1080 cells, we produced
pools of transfectants stably expressing GFP fusion proteins of
FLIPL and FLIPS, respectively. All FLIPL/S expressing KB and
HT1080 populations (KB-FLIPL/S-GFP and HT1080-FLIPL/S-
GFP) showed unchanged Fas expression (not depicted) and
were highly resistant against FasL-induced apoptosis also in
the presence of CHX (Fig. 6, A and B). Although in z-VAD-
fmk– and Bcl2-protected KB and HT1080 cells FasL strongly
induced IL8 production, in FLIPL- and FLIPS-protected cells
Fas-mediated IL8 up-regulation was blocked (Fig. 6, C and
D). The inhibitory effect of FLIPL and FLIPS on IL8 produc-
tion was specific for Fas, as TNF-induced IL8 up-regulation,
Figure 4. FasL-induced I B  up-regulation occurs via a FADD, 
caspase-8, RIP-dependent pathway in Jurkat cells. (A and B) RIP- 
(A), NEMO/IKK - (A), FADD- (B), and caspase-8 (B)–deficient Jurkat 
clones and the corresponding parental cell lines were treated for 6 h 
with the indicated combinations of M2–cross-linked Flag-FasL (200 
ng/ml), TNF (20 ng/ml), and z-VAD-fmk (20  M). Total RNAs were 
isolated for RPA analyses and 10  g of each RNA sample were 
analyzed with a Multi-Probe template set containing probes for the 
indicated mRNAs. Parental Jurkat cells were challenged with cross-
linked FasL alone, but a reliable RPA analysis was not possible due 
to the massive induction of apoptosis leading to a strong reduction 
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which occurs via the Fas-related death receptor TNF-R1, only
insignificantly varied for maximally 33% between the parental
cells and the corresponding transfectants. Changes in basal
IL8 production were negligible in the FLIPL/S-transfected KB
populations (Fig. 6, C and D). However, the FLIPL and espe-
cially the FLIPS-expressing HT1080 cells showed significantly
increased levels of constitutive IL8 production (Fig. 6, C and
D). Similar effects were also found in respect to NF B activa-
tion (unpublished data). Thus, dependent on the cell type,
FLIPS and to a lesser extend FLIPL can have opposing effects,
namely inhibition of Fas-inducible NF B activation and up-
regulation of NF B by another yet unknown mechanism.
FACS
® analysis of the FLIP-GFP–expressing cells and EGFP
FACS
® calibration beads showed that 60–80% of the KB
transfectants expressed  116,000 molecules of the GFP fu-
sion proteins per cell, whereas the rest of the cells expressed
 116,000 molecules per cell (Fig. 6 A). In TNF-stimulated
KB cells (Fig. 7 B), mature DCs, and, as a positive control in
the Hodgkin cell line L591 (Fig. 5), endogenous expression of
FLIPL reached 0.25, 4, and 3 fg per cell; and FLIPS reached
0.5 and 6 fg per cell in KB and L591 cells. This corresponds
to  3,000 to 50,000 FLIPL molecules and 15,000 to 180,000
FLIPS molecules per cell. As the inhibitory effects on FLIPL-
GFP and FLIPS-GFP expression in KB cells were around 90%
(Fig. 6 D), these data indicate that “physiological” levels of
FLIPL and FLIPS are sufficient to block FasL-induced IL8
production. Next, we down-regulated expression of endoge-
nous FLIP proteins by RNA interference–mediated gene si-
lencing using the synthetic small interfering RNA (siRNA)
F1, recognizing both FLIP isoforms (Fig. 7 A; Siegmund et
al., 2002), and a new siRNA, F1490, which down-regulate
FLIPL but not FLIPS (Fig. 7, A and B). In KB cells electropo-
rated with the FLIP-specific siRNAs, FasL-induced IL8 pro-
duction was substantially enhanced, as compared with cells
mock electroporated or electroporated with control siRNA
(Fig. 7 C). The increase of FasL-induced IL8 production
Figure 5. FLIPL inhibits FasL-induced I B  up-regulation. (A) 10
6 L591 Hodgkin, KB, or Jurkat FLIPL cells were treated for the indicated 
times with 50  g/ml CHX and were analyzed with respect to expression of FLIPL and FLIPS by Western blotting with a FLIP-specific antibody. 
To control protein loads, filters with L951 and KB cells were reprobed with an antitubulin antibody, and a FLIPL-GFP mass standard, which 
was normalized via its GFP part, was processed on the same filter to allow a quantitative estimation of FLIP expression. Based on this standard, 
FLIPL expression corresponds to 3,000 (KB) and 36,000 (L591) molecules per cell and FLIPS expression to 15,000 (KB) and 180,000 (L591) 
molecules per cell. (B) Parental Jurkat cells and a clone derived thereof, which stably overexpresses FLIPL, were challenged with the indicated 
combinations of soluble Flag-tagged FasL (200 ng/ml) cross-linked with the Flag-specific mAb M2 (0.5  g/ml), TNF (20 ng/ml), and z-VAD-
fmk (20  M) for 6 h; and 10  g of total RNA were used for RPA analyses with respect to the expression of the indicated target genes. (C) Cell 
lysates corresponding to 10
6 primary T cells, immature and mature DCs, and Jurkat-FLIPL transfectants were analyzed with respect to expression 
of FLIPL and FLIPS by Western blotting with a FLIP-specific antibody. Based on the FLIPL-GFP mass standard, FLIPL expression corresponds to 
50,000 molecules per cell in mature DCs and Jurkat-FLIPL cells. (D) Human (left) and murine T cell blasts (right) as well as fully mature hu-
man dendritic cells (DCs; middle) were challenged for 6 h with M2–cross-linked Flag-FasL (200 ng/ml) in the presence of z-VAD-fmk. Total 
RNAs were finally analyzed with respect to expression of the indicated genes by RPA analysis.376 The Journal of Cell Biology | Volume 166, Number 3, 2004
reached by siRNA treatment was comparable, although FLIPS
expression significantly exceeded FLIPL expression in KB cells
(Fig. 5 A and 7 B). This finding suggests that FLIPL is more
efficient than FLIPS in inhibition of Fas-induced NF B acti-
vation. Basal IL8 production was also specifically increased in
F1490- and F1-siRNA electroporated cells (Fig. 7 C). Thus,
although in HT1080 cells that ectopically expressed FLIPS or
FLIPL basal IL8 production was increased, endogenously ex-
pressed FLIP had an inhibitory role in KB cells. These oppos-
ing effects on Fas-independent basal IL8 production might re-
flect cell type–specific and/or FLIP isoform–specific functions
of FLIP not related to Fas signaling (see Discussion).
Discussion
The Fas-induced signaling pathways leading to up-regula-
tion of I B  and cJun were completely blocked in
FADD- and caspase-8–deficient Jurkat cells in our study
(Fig. 4 B). Moreover, induction of apoptosis and necrosis
as well as up-regulation of cFos, which most likely occurs
via the ERK pathway, have also been reported to be
blocked in the FADD-deficient Jurkat clone used in our
study (Juo et al., 1999; Holler et al., 2000; Siegmund et
al., 2001). Further, with the exception of necrosis induc-
tion, all these Fas-induced processes are also abrogated in
caspase-8–deficient Jurkat cells (Juo et al., 1998; Holler et
al., 2000; Siegmund et al., 2001). Together this suggests
that upon stimulation Fas forms a core signaling complex
with FADD, which is essentially involved in all Fas-medi-
ated signaling pathways (Fig. 8). With the exception of
necrosis induction, caspase-8 is necessary for all other Fas
signaling events. Noteworthily, only apoptosis induction
appears to be dependent on the proteolytic activity of cas-
pase-8 arguing for an additional scaffolding-related func-
tion of caspase-8 in context of the Fas signaling complex.
Although RIP is necessary for Fas-induced NF B activa-
tion (Fig. 4 A) and necrosis induction (Holler et al.,
2000), this kinase seems dispensable for the pathway(s)
Figure 6. FLIPL and FLIPS protect HT1080 and KB cells from 
Fas-mediated apoptosis and block FasL-induced IL8 production. 
(A) FACS
® analysis of GFP FACS
® calibration beads with 0 (labeled 
“A”), 4,500 (labeled “B”), 15,000 (labeled “C”), 44,000 (labeled 
“D”), and 116,000 (labeled “E”) molecules of equivalent soluble 
fluorochrome as well as HT1080 and KB cell stably transfected with 
FLIPL-GFP or FLIPS-GFP. In the case of the KB cells, the localization 
of the calibration beads was corrected according to a minor differ-
ence in the autofluorescence of the parental cells and the nonfluo-
rescent beads. (B) Indicated cells were seeded in 96-well plates 
(20   10
3 per well) and challenged with the indicated concentrations 
of soluble Flag-tagged FasL complexed with 0.5  g/ml of the Flag-
specific mAb M2 in the presence of 2.5  g/ml CHX the next day. 
After an additional 18 h, cell viability was determined by crystal 
violet staining. (C) The indicated transfectants and cell lines were 
seeded in 96-well plates (20   10
3 per well). The next day, the 
medium was changed and cells were stimulated in triplicates with 
the indicated combinations of 200 ng/ml of cross-linked Flag-FasL, 20 ng/ml TNF, 20  M z-VAD-fmk, and 2.5  g/ml CHX. After 6 h, super-
natants were removed and cleared, and IL8 concentrations were determined by ELISA analysis. (D) HT1080 and KB cells and FLIPL-GFP and 
FLIPS-GFP transfectants derived thereof were challenged for 6 h with 200 ng/ml of M2–cross-linked Flag-FasL or 20 ng/ml TNF in the presence 
of 20  M z-VAD-fmk (HT1080) or a mixture of 2.5  g/ml CHX and 20  M Z-VAD-FMK (KB). Total RNAs were isolated and the expression of 
the indicated genes was determined by RPA analysis.FLIP inhibits Fas-induced NF B activation | Kreuz et al. 377
leading to up-regulation of cJun and cFos (Fig. 4; Sieg-
mund et al., 2001). For the reasons outlined in the next
paragraph in detail, FLIPL/S appear to have an inhibitory
role for all of these Fas-dependent signaling events by tar-
geting the Fas/FADD–caspase-8 core complex. However,
there is also evidence in the literature for Fas-independent
signaling properties of FADD, caspase-8, and FLIP.
Transient overexpression experiments have revealed NF B-
inducing capacities of FADD, caspase-8, FLIPL, and FLIPS
(Chaudhary et al., 2000; Hu et al., 2000; Wajant et al.,
2000). Moreover, several studies have shown that stimula-
tion of Fas can also result in NF B activation, suggesting at
first glance that a FADD/caspase-8/FLIPL (or FLIPS)–con-
taining complex mediates this response (for review see
Leverkus et al., 2003; Wajant et al., 2003). However, there
are several concerns arguing against this simple concept.
NF B activation by overexpression of FADD, FLIPL, or
FLIPS is blocked by proteins (CrmA and p35) and reagents
(BD-fmk and z-VAD-fmk) that prevent caspase-8 activation
(Chaudhary et al., 2000; Hu et al., 2000). In contrast,
NF B activation induced by overexpressed caspase-8 or
stimulated Fas are rather enhanced by inhibition of cas-
pase-8 activity (Chaudhary et al., 2000; Hu et al., 2000; Wa-
jant et al., 2000). Nevertheless, as shown in Fig. 4 B, FasL-
induced up-regulation of I B  was completely absent in
FADD and caspase-8–deficient cells. Thus, it seems possible
that FADD and caspase-8 are not only necessary for caspase
activity–independent Fas-induced NF B activation but may
also act in a Fas-independent but caspase activity–dependent
NF B-inducing pathway. We have further identified in this
study RIP as an essential component of Fas-induced NF B
signaling. In accordance with this finding, it has been re-
ported that a dominant-negative deletion mutant of RIP
blocks NF B activation induced by transiently overex-
pressed FADD and Fas (Hu et al., 2000). Notably, in this
study, dominant-negative RIP failed to inhibit NF B activa-
tion by overexpressed FLIP (Hu et al., 2000), arguing again
for the existence of a Fas-independent role of FLIP in a yet
unknown pathway leading to NF B activation. Further,
RIP is cleaved by caspase-8, resulting in an NF B-inhibitory
fragment (Lin et al., 1999). Recent studies suggest that enzy-
matically active heteromers of caspase-8 and FLIPL can be
formed within the Fas signaling complex. Thus, the FLIPL-
arrested DISC may also lead to the cleavage of RIP arguing
Figure 7. Down-regulation of endoge-
nous FLIPL is sufficient to enhance Fas-
mediated IL8 production. (A) Expression 
plasmids for FLIPL-GFP, FLIPS-GFP, and 
DsRED were transiently transfected in 
triplicate with siRNAs (150 nM) specific 
for GFP (S15), FLIPL (F1490), or for both 
FLIP isoforms (F1). As a control, the vari-
ous plasmids were cotransfected with a 
Bcl2-specific siRNA. After 48 h, cells 
were analyzed by FACS
®, and relative 
expression levels were calculated from 
the product of the percentage of positive 
cells and the mean fluorescence intensity 
of positive cells. (B) The indicated siRNAs 
(150 nM) were introduced into KB cells 
by electroporation. The next day, expres-
sion of FLIPL and FLIPS was up-regulated by TNF stimulation (20 ng/ml) and determined 
by Western blot analysis of cell extracts with a FLIP-specific antibody. To control protein 
loads, filters were reprobed with antitubulin antibodies. (C) KB cells were seeded in 96-
well plates (20   10
3 per well). 1 d later, cells were mock transfected (open bars) or trans-
fected with control siRNA (hatched bars), a FLIPL/S-specific siRNA (F1; black bars), or a 
FLIPL-specific siRNA (F1490; gray bars). After an additional day, medium was changed 
and cells were stimulated for 6 h with 200 ng/ml of M2–cross-linked Flag-FasL or 20 ng/ml 
TNF. Finally, IL8 production was measured by ELISA analysis.
Figure 8. Model of Fas signaling pathways. Relations 1–3, 7–9, 
and 10 are based on literature data (see Discussion for details). 
Relations 3–6 are evident from data shown in Fig. 5. Relations 11–13 
are based on experiments shown in Figs. 1–4 and 7.378 The Journal of Cell Biology | Volume 166, Number 3, 2004
against an NF B-activating role of FLIPL in Fas signaling. It
should be briefly mentioned here that Fas also induces ne-
crosis in Jurkat cells under crucial involvement of RIP, but
independent from NEMO/IKK  (Holler et al., 2000; un-
published data). Thus, Fas-induced NF B and necrosis sig-
naling bifurcate at the level or downstream of RIP (Fig. 8).
The Fas-independent NF B-inducing capabilities of FLIPL/S
might be related to the NF B-activating properties of the vi-
ral FLIP homologue HHV8 vFLIP that interacts with the
IKK complex (Liu et al., 2002; Field et al., 2003). Indeed,
similarly to overexpressed FLIPL/S, HHV8 vFLIP activates
NF B independent of RIP (Matta et al., 2003). Moreover,
HT1080 cells stably transfected with FLIPS, which is more
closely related in its domain architecture to HHV8 vFLIP
than FLIPL, showed a significantly higher basal NF B activ-
ity than FLIPL-expressing HT1080 cells (Fig. 6). FLIP ef-
fects not related to Fas signaling might also be based on the
recently described interaction of FLIPL with NF B1/p105
(Li et al., 2003) and p38MAPK (Grambihler et al., 2003).
Opposing effects of FLIP have also been reported with re-
spect to T cell activation. Although overexpressed FLIPL en-
hances TCR-induced ERK activation and IL2 production in
Jurkat cells, it reduces these responses in DO11.10 T cells
(Fang et al., 2004). Moreover, in one study, increased prolif-
eration in FLIP-transgenic T cells upon stimulation with
suboptimal concentrations of anti-CD3 has been observed
(Lens et al., 2002), whereas in another study several trans-
genic lines with T cell–restricted FLIP expression exerted
suppression of T cell activation over a wide range of anti-
CD3 concentrations (Tai et al., 2004). However, the precise
effects of FLIP on Fas signaling had not been addressed in
these studies as no experiments with Fas stimulation have
been performed. In KB and HT1080 cells, Bcl2 overexpres-
sion increased the ED50 value for FasL-induced apoptosis
more than 500-fold (Fig. 1 B), suggesting an almost essential
contribution of the intrinsic apoptotic pathway to Fas-
induced apoptosis. However, in vivo, a significant contribu-
tion of the intrinsic pathway has so far only been observed in
some studies when Fas was challenged with Fas-specific ago-
nistic antibodies, making the physiological relevance of the
intrinsic pathway for the in vivo effects of Fas a matter of de-
bate. However, it should be taken into consideration that
not only the specific cell type is of relevance for the question
of whether a contribution of the intrinsic pathway to Fas-
induced apoptosis gets apparent but also the strength of Fas
activation and the time point after Fas triggering. Indeed, it
has been shown in vitro that agonistic Fas antibodies alone
are significantly less efficient than cross-linked soluble FasL
or secondary aggregated Fas antibodies to kill type II cells
(Huang et al., 1999). Noteworthily, in the studies showing
protection against Fas-induced liver failure in Apaf1- (Cec-
coni et al., 1998), Bid- (Yin et al., 1999), or Bax- and Bak
(Wei et al., 2001)-deficient mice, a suboptimal amount of
agonistic antibodies was used to activate Fas. In contrast,
in a study that fails to observe Bcl2-mediated protection
against the hepatotoxic effects of Fas activation, cross-linked
FasL was used (Huang et al., 1999). This suggests that there
is no essential role of the intrinsic pathway in Fas-induced
apoptosis in vivo but rather an accelerative and/or enhancing
contribution, especially after a limited activation of Fas. De-
layed apoptosis induction via Fas should already be suffi-
cient to allow transient activation of the NF B pathway by
the mechanisms described in our study and might be of spe-
cial relevance for the proinflammatory effects of FasL ob-
served in various models of FasL-mediated tumor rejection.
Although Fas-induced NF B activation depends on caspase-8,
the enzymatic activity of the latter appeared to be dispens-
able (Figs. 2–5). Thus, Fas-induced NF B activation may
attain importance under pathophysiological conditions where
caspase-8 activity is blocked, e.g., by viral inhibitors such as
CrmA or where caspase-8 is mutated.
Materials and methods
Reagents
Human recombinant Flag-tagged soluble FasL was purified from superna-
tants of Hek293 cells stably transfected with a corresponding expression
plasmid by affinity chromatography with anti-FLAG M2 agarose beads
(Sigma-Aldrich). Human recombinant TNF was obtained from Knoll AG.
z-VAD-fmk was purchased from Bachem and z-IETD-fmk was obtained
from Calbiochem. CHX, the anti-Flag mouse mAb M2, and alkaline phos-
phatase–conjugated goat anti–mouse IgG were purchased from Sigma-
Aldrich. The anti-FLIP mouse mAb NF-6 was purchased from Qbiogene.
The human epidermal cell line KB and the human fibrosarcoma cell line
HT1080 were both obtained from the American Type Culture Collection.
The Jurkat T cell lines deficient for FADD, caspase-8, NEMO/IKK , and RIP
were supplied by J. Blenis (Harvard Medical School, Boston, MA), B. Seed
(Massachusetts General Hospital, Boston, MA), and S.-C. Sun (Pennsylva-
nia State University College of Medicine, Hershey, PA) and are described
elsewhere (Ting et al., 1996; Juo et al., 1998, 1999; Harhaj et al., 2000).
The Jurkat clones overexpressing FLIPL and FLIPS, respectively, were sup-
plied by P. Schneider and J. Tschopp (University of Lausanne, Epalinges,
Switzerland) and are described by Irmler et al. (1997). The F1 siRNA corre-
sponds to positions 472–494 of U97074 (sense: 5 -atgtggttccacctaatgtca-
3 ; antisense: 5 -tgacattaggtggaaccacatct-3 ) and F1490 to positions 1785
to 1805 whereby A1788 was substituted to G to match the mouse se-
quence (sense: 5 -agcacacucugaggaagaaac-3 ; antisense: 5 -guuucuuccu-
cagagugugcugc-3 ).
Cell culture
KB, HT1080, and Jurkat cells were maintained in RPMI 1640 medium con-
taining 10% heat-inactivated FCS in a humified 5.0% CO2 environment.
For generation of polyclonal cell populations stably overexpressing GFP-
fusion proteins, 10   10
6 cells were electroporated (4 mm cuvette; 250 V,
1800  F, maximal resistance) with 10  g of plasmid DNA in medium with
5% FCS. After 14 d of selection with 400–800  g/ml G418 (GIBCO BRL),
primary clones (n   100) were pooled, expanded, and enriched for cells
expressing the GFP-fusion proteins by two to three rounds of cell sorting
using a FACStar
Plus (Becton Dickinson). A Fas-negative, CD3-responsive
Jurkat subclone (Janssen et al., 1996) was electroporated with a pEFBos-
derived vector encoding full-length FasL and a hygromycin resistance vec-
tor (provided by B. Schraven, Otto-von-Guericke-University, Magdeburg,
Germany). Resistant clones (Rapo-FasL) obtained were selected for high
FasL membrane expression and subcloned under limiting dilution condi-
tions. Human monocyte-derived dendritic cells were prepared and charac-
terized as recently described (Leverkus et al., 2003). Human and murine T
cells were prepared as described by Glauner et al. (2002) and Mack and
Hacker (2002), respectively.
Cell death assays, Western blotting, and electrophoretic mobility 
shift assay analysis
These techniques were performed as described previously (Wajant et al.,
2000; Kreuz et al., 2001).
IL8-ELISA
Cells were seeded in 96-well cell culture plates and cultivated overnight.
The next day, the cell culture medium was exchanged and cells were stim-
ulated with the reagents of interest for 6 h, and the IL8 concentrations
reached in the supernatants were determined using the OptEIA™ human
IL8 Set (BD Biosciences) according to the supplier’s protocols. After sub-
traction of the extinction of the medium control, IL8 concentrations were
calculated based on IL8 standards included in the analysis.FLIP inhibits Fas-induced NF B activation | Kreuz et al. 379
RNase protection assay (RPA)
Cells were treated as indicated, washed, and stored at  80 C until total
RNAs were prepared with the peqGOLD RNAPure reagent (PeqLab Bio-
technologie GmbH) according to the manufacturer’s instructions. Total
RNAs were analyzed using customer Multi-Probe template sets (BD Bio-
sciences) with respect to the expression of the indicated genes. Probe syn-
thesis, hybridization, and RNase treatment were performed with Ribo-
Quant In vitro transcription and RiboQuant Multi-Probe RNase Protection
Assay Systems (BD Biosciences) according to the manufacturer’s recom-
mendations. After RNase treatment, the protected transcripts were resolved
by electrophoresis on a denaturing polyacrylamide gel (5%) and analyzed
using a PhosphorImager operated by the ImageQuant software (Molecular
Dynamics).
DNA oligonucleotide microarray analysis
The customized DNA microarray used in this study contains three oligonu-
cleotide probes per gene for 110 genes relevant for inflammation. The
specificity of the probes has been validated as described in detail previ-
ously (Holzberg et al., 2003). Fluorescent cRNA were prepared by reverse
transcription of 3–5  g of total RNA. Specifically, RNA was treated with
DNase and double-stranded cDNAs followed by fluorophore-cRNAs that
were synthesized using the cDNA synthesis system (Roche) and the
MEGAscript T7 kit (Ambion) as directed by the manufacturers. 80 to 250
ng of double-stranded cDNA and 1.25 mM Cy3-UTP were used in each
cRNA labeling reaction. Equal amounts (9  g) of labeled cRNAs from each
condition were hybridized individually to the DNA microarray in prepre-
pared hybridization solution (MWG Biotech) at 42 C overnight and then
washed sequentially in 2  SSC, 0.1% SDS, 1  SSC, and 0.5  SSC. Hy-
bridized arrays were scanned at maximal resolution on a scanner (model
428; Affymetrix, Inc.). Fluorescence intensity values from TIFF images of
Cy3 channels were integrated into one value per probe, normalized by the
MAVI software (MWG Biotech), and further analyzed using Imagene 4.2
software (Biodiscovery). Genes whose expression changed by 1.5-fold on
average and by at least 1.3-fold in each individual experiment were con-
sidered to be regulated by TNF or FasL, respectively. Genes whose expres-
sion ratio did not change were considered to be significantly expressed if
the normalized signal intensity measured for this gene was two SDs higher
than the average signal intensity obtained by comparing microarray results
from five different cell lines.
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